Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine.

BNT162b2 mRNA vaccine SARS-CoV-2 cellular immunity fuzzy system humoral immunity

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
22 Jan 2022
Historique:
received: 18 12 2021
revised: 15 01 2022
accepted: 20 01 2022
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 27 2 2022
Statut: epublish

Résumé

We have designed a prospective study aiming to monitor the immune response in 178 health care workers six months after BNT162b2 mRNA vaccination. The humoral immune response of all subjects was evaluated by chemiluminescence (CMIA); in 60 serum samples, a live virus-based neutralization assay was also tested. Moreover, 6 months after vaccination, B- and T-cell subsets from 20 subjects were observed by FACS analysis after restimulation with the trimeric SARS-CoV-2 Spike protein as an antigen, thus mimicking reinfection in vitro. A significant decrease of circulating IgG levels and neutralizing antibodies over time were observed. Moreover, six months after vaccination, a variable T-cell immune response after in vitro antigen stimulation of PBMC was observed. On the contrary, the analysis of B-cell response showed a shift from unswitched to switched memory B-cells and an increase of Th17 cells. Although the variability of the CD4

Sections du résumé

BACKGROUND BACKGROUND
We have designed a prospective study aiming to monitor the immune response in 178 health care workers six months after BNT162b2 mRNA vaccination.
METHODS METHODS
The humoral immune response of all subjects was evaluated by chemiluminescence (CMIA); in 60 serum samples, a live virus-based neutralization assay was also tested. Moreover, 6 months after vaccination, B- and T-cell subsets from 20 subjects were observed by FACS analysis after restimulation with the trimeric SARS-CoV-2 Spike protein as an antigen, thus mimicking reinfection in vitro.
RESULTS RESULTS
A significant decrease of circulating IgG levels and neutralizing antibodies over time were observed. Moreover, six months after vaccination, a variable T-cell immune response after in vitro antigen stimulation of PBMC was observed. On the contrary, the analysis of B-cell response showed a shift from unswitched to switched memory B-cells and an increase of Th17 cells.
CONCLUSIONS CONCLUSIONS
Although the variability of the CD4

Identifiants

pubmed: 35214630
pii: vaccines10020171
doi: 10.3390/vaccines10020171
pmc: PMC8879995
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14292-7
pubmed: 20660725
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Am J Pathol. 2012 Jul;181(1):8-18
pubmed: 22640807
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
PLoS Pathog. 2021 Dec 28;17(12):e1010211
pubmed: 34962970
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Cells. 2021 Sep 26;10(10):
pubmed: 34685521
J Med Virol. 2021 Apr;93(4):2548-2552
pubmed: 33427302
PLoS One. 2012;7(11):e49715
pubmed: 23166752
J Allergy Clin Immunol. 2016 May;137(5):1577-1584.e10
pubmed: 26525227
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Immunol. 2022 Jan;23(1):33-39
pubmed: 34848871
Front Immunol. 2020 Dec 16;11:610300
pubmed: 33391280
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet. 2021 Apr 17;397(10283):1421-1423
pubmed: 33844964

Auteurs

Claudia Gandolfo (C)

Virology Unit, Department of Medical Biotechnologies, University of Siena, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Gabriele Anichini (G)

Virology Unit, Department of Medical Biotechnologies, University of Siena, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Marco Mugnaini (M)

Department of Information Engineering and Mathematical Sciences, University of Siena, 53100 Siena, Italy.

Monica Bocchia (M)

Hematology Unit, Department of Medical Sciences, Surgery and Neurosciences, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Chiara Terrosi (C)

Virology Unit, Department of Medical Biotechnologies, University of Siena, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Anna Sicuranza (A)

Hematology Unit, Department of Medical Sciences, Surgery and Neurosciences, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Gianni Gori Savellini (G)

Virology Unit, Department of Medical Biotechnologies, University of Siena, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Alessandro Gozzetti (A)

Hematology Unit, Department of Medical Sciences, Surgery and Neurosciences, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Federico Franchi (F)

Anesthesia and Intensive Care Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.

Maria Grazia Cusi (MG)

Virology Unit, Department of Medical Biotechnologies, University of Siena, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Classifications MeSH